Real World Data On The Clinical Efficacy And Safety Of Ixekizumab In The Treatment Of Moderate To Severe Psoriasis

Background Psoriasis is mediated skin immune system,and its characteristics of easy to break out repeatedly plagued many patients,not only damage the skin and joints,the comorbidity may seriously affect the patients life,is the typical clinical symptoms of psoriasis skin thickening,the red areas covered silver scales,around the red patches of different size and degree of,the metabolic syndrome and risk of cardiovascular disease in patients with moderately severe psoriasis,for patients with more serious impact on quality of life and mental health,there are about 0.47% of China’s psoriasis people involvement Traditional drug therapy often fails to achieve desired results,and recently helper T cell 17(Th17),an innate and adaptive immune regulator,has been found to play an important role in reducing the autoimmune inflammatory cascade and phenotypic changes associated with psoriasis Ixekizumab bead sheet resistance,therefore,as a kind of humanized monoclonal antibody,can combine with specificity and inhibition of interleukin(IL)-17 a has been developed,the main and interleukin 17 after a combination of biological agents at the same time and biological activities of cytokines,2016 Ixekizumab bead sheet resistance by health authorities around the world approved type used in the treatment of adult patients with moderately severe plaque psoriasis this paper observed in 34 patients with moderately severe plaque psoriasis treatment with Ixekizumab bead sheet resistance to 12 weeks after the clinical curative effect and adverse reaction in treatment and countermeasures of adverse reactions Real-world data on Ixekizumab in the treatment of moderate to severe plaque psoriasis are scarce in China.Currently,knowledge about the efficacy and safety of Ixekizumab is limited to data from phase III randomized controlled trials(RCTs)Objective(1)Systematic evaluation of the clinical efficacy of Ixekizumab in the treatment of patients with plaque psoriasis(2)To evaluate the adverse reactions of Ixekizumab in the treatment of plaque psoriasis(3)Assess the correlation between the patient’s clinical outcome after 8 weeks of treatment and the patient’s baselineMethods The purpose of this study was to observe the efficacy and safety of Ixekizumab in the treatment of moderate and severe plaque psoriasis after 12 weeks.The lesions severity score(PASI)was used to evaluate the patients’ condition improvement after treatment with Ixekizumab every two weeks in patients 24,68,10 respectively12 weeks to subcutaneous injection of 80 mg,week 0 to 160 mg Ixekizumab bead sheet resistance,and collected from 34 patients of some basic information,including the patient’s age,gender,course of diseases,basic diseases,etc.,at the same time evaluate patients in the use of Ixekizumab bead sheet resistance to 8 weeks after the curative effect and the correlation between the baseline data of patients,through logica pasi score patients with single factor analysis to understand the patient’s gender,age,duration,onset age,drinking,smoking and the patient’s basic diseases such as diabetes,high blood pressure,blood fat,and so on and so forth During and at the same time pay attention to these nails and nail psoriasis patients is damaged,the head condition improved after treatment in patients with psoriasis,and health assessment questionnaire survey carried out on the patient,the patient dermatology life quality index(DLQI),the doctor’s comprehensive evaluation,in the observation curative effect in the process of patient evaluation and record adverse reactions,in order to assess the safety of the biological agentsResults 34 patients with moderately severe plaque psoriasis patients be incorporated in this study,we respectively in patients before use,use 4 weeks,8 weeks,12 weeks after patients with curative effect evaluation,four weeks,patients in the use of PASI75 for 38.2%,achieve PASI90 11.8%,achieve PASI100 is 2.9%,8 weeks of patients with PASI75,PASI90,PASI100 respectively is 88.2%,61.8%,29.4% to 12 weeks of ratio of 100%,88.2%,76.5% of patients in 0 weeks 4 weeks,8 weeks The mean PASI score at 12 weeks was 18.72±9.79,6.35 ±5.36,2.58 ±3.15,1.7 ±2.19.Baseline changes at 4,8,and 12 weeks compared to 0 weeks were analyzed by t-test.Patients’ quality of life score was 14.94 ±5.73 at baseline,which dropped to 1.7 ±1.17 after 12 weeks of treatment.0.01,the difference is statistically significant,patient quality of life scores improved significantly after treatment In the 34 patients with 10 patients by using ixekizumab bead mild-tomoderate adverse reactions,a local injections of reaction is the most common adverse reactions,including 3 cases with pain at the injection site redness,2 cases with itchy at the injection site,2 cases is the common cold,1 case had urticaria,1 case with conjunctivitis,1 case with back pain,1 case of facial dermatitis There are 2 patients discontinued because of a drug side effects,1 case is more severe urticaria,1 case appeared facial dermatitis and stop to use.